[^1]
[^2]
[^3]
[^4]
[^5]
[^6]
[^7]
[^8]
| Full Name | Nuclear Receptor Binding SET Domain Protein 2 |
| Gene Symbol | NSD2 |
| Aliases | WHSC1, MMSET |
| Chromosomal Location | 4p16.3 |
| NCBI Gene ID | 7468 |
| OMIM | 602952 |
| Ensembl | ENSG00000109685 |
| UniProt | O96028 |
| Protein | Histone-lysine N-methyltransferase NSD2 |
| Associated Diseases | Wolf-Hirschhorn syndrome, Alzheimer's disease, intellectual disability, growth retardation |
GSK3β is a human gene. Variants in GSK3β have been implicated in Wolf-Hirschhorn Syndrome, Alzheimer's Disease, Seizure Disorders. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
NSD2 (also known as WHSC1/MMSET) encodes a histone lysine methyltransferase of the NSD family that catalyzes dimethylation of histone H3 at lysine 36 (H3K36me2). NSD2 is the primary enzyme responsible for maintaining genome-wide H3K36me2 levels, a histone mark associated with active transcription and intergenic chromatin regulation. NSD2 resides in the critical region of the 4p16.3 deletion responsible for Wolf-Hirschhorn syndrome (WHS), and its haploinsufficiency is considered the primary driver of the cognitive and developmental phenotypes in WHS.
NSD2 is a 1365-amino acid protein containing:
- SET domain: The catalytic methyltransferase domain that specifically dimethylates H3K36
- PWWP domain: Reads existing H3K36 methylation marks, enabling processive methylation along gene bodies
- PHD fingers (4x): Recognize various histone tail modifications for chromatin context-dependent activity
- HMG box: Provides non-sequence-specific DNA binding capability
- AWS (associated with SET) domain: Stabilizes the SET domain catalytic fold
NSD2 regulates neural gene expression through multiple interconnected mechanisms:
- Intergenic H3K36me2: NSD2 is responsible for >80% of H3K36me2 in intergenic regions, where this mark prevents aberrant PRC2-mediated H3K27me3 spreading. NSD2 loss causes redistribution of H3K27me3 across the genome, silencing neural genes
- Enhancer priming: H3K36me2 at enhancers facilitates recruitment of DNMT3A, establishing DNA methylation patterns critical for neural lineage specification
- DNA damage repair: NSD2 is recruited to DNA double-strand breaks where it methylates H3K36 to facilitate recruitment of NHEJ repair factors including Ku70/Ku80 and 53BP1
- Cell cycle regulation: NSD2 promotes expression of cyclin and CDK genes required for neural progenitor proliferation during brain development
- Transcriptional elongation: Gene body H3K36me2 deposited by NSD2 supports productive transcriptional elongation, particularly important for the large genes that predominate in neuronal transcriptomes
¶ Neural Expression and Brain Distribution
NSD2 is broadly expressed throughout the developing and adult brain:
- Developing brain: Peak expression during mid-embryonic neurogenesis (E12-E16 in mouse), coinciding with cortical neurogenesis and migration
- Hippocampus: Strong expression in CA1-CA3 and dentate gyrus, reflecting roles in memory-associated chromatin plasticity
- Cerebral cortex: Expression across cortical layers with enrichment in deep-layer projection neurons
- Cerebellum: Purkinje cell and granule cell expression; cerebellar hypoplasia is a feature of Wolf-Hirschhorn syndrome
- Adult brain: Maintained expression with particular enrichment in neurons and oligodendrocytes
Heterozygous deletion of the 4p16.3 region containing NSD2 causes Wolf-Hirschhorn syndrome (WHS), characterized by severe intellectual disability, seizures (>90% of patients), distinctive facial features, growth retardation, and microcephaly. NSD2 haploinsufficiency is considered the primary contributor to the neurodevelopmental phenotype, as:
- Point mutations in NSD2 alone can recapitulate intellectual disability without the full WHS spectrum
- NSD2 heterozygous knockout mice show learning deficits, altered dendritic arborization, and reduced hippocampal long-term potentiation (LTP)
- H3K36me2 levels are globally reduced in WHS patient cells, causing widespread epigenomic dysregulation
NSD2 has several connections to AD pathogenesis:
- Epigenetic aging: Age-dependent decline in NSD2 expression contributes to progressive H3K36me2 loss, enabling PRC2-mediated silencing of neuroprotective genes
- Tau modification: NSD2-dependent H3K36me2 regulates expression of tau kinases including GSK3β and CDK5; H3K36me2 loss alters the tau phosphorylation landscape
- Amyloid processing: PBAF/BAF complexes interact with NSD2-methylated chromatin at the APP and BACE1 loci; NSD2 loss may dysregulate amyloidogenic processing
- Neuroinflammation: NSD2 represses inflammatory gene expression in microglia through intergenic H3K36me2; its decline permits pro-inflammatory gene activation
90% of WHS patients develop seizures, often refractory to treatment. NSD2 haploinsufficiency disrupts expression of ion channel genes including SCN1A, KCNQ2, and GABA receptor subunits, providing a molecular basis for WHS-associated epilepsy.
| Variant |
Type |
Population Frequency |
Clinical Significance |
| 4p16.3 deletion |
CNV |
Rare (1:50,000) |
Wolf-Hirschhorn syndrome |
| p.Glu1099Lys (E1099K) |
Missense (gain-of-function) |
Somatic |
ALL, multiple myeloma |
| p.Thr1150Ala |
Missense |
Rare |
Intellectual disability |
| rs7660520 |
Intronic |
0.15 (global) |
Cognitive function GWAS signal |
- NSD2 inhibitors: Small-molecule inhibitors targeting the SET domain of NSD2 (e.g., UNC6934) are in preclinical development for NSD2-overexpressing cancers; CNS penetrance and neurological safety require careful evaluation
- EZH2 inhibitors: Since NSD2 loss causes H3K27me3 expansion, EZH2/PRC2 inhibitors (tazemetostat) could potentially rescue gene silencing in NSD2-haploinsufficient neurons
- HDAC inhibitors: Broad chromatin-opening agents may partially compensate for NSD2-mediated accessibility loss, though selectivity remains challenging
- Gene dosage therapy: For WHS, AAV-mediated NSD2 supplementation could restore H3K36me2 levels; feasibility is limited by the large NSD2 transcript (~4.1 kb CDS)
- Seizure management: Understanding NSD2-dependent ion channel gene regulation may guide anticonvulsant selection in WHS patients
- NSD1 — H3K36 methyltransferase, Sotos syndrome
- SETD2 — H3K36 trimethyltransferase
- KDM6B — H3K27 demethylase
- EZH2 — PRC2 component, H3K27 methyltransferase
- ARID2 — PBAF chromatin remodeler
- BRD4 — Bromodomain reader protein